A major 35-year prospective study of over 4,300 American adults found no significant association between cumulative lifetime cannabis use and the development of high blood pressure. While methodologically rigorous, the findings primarily reflect light-to-moderate use patterns and should not be interpreted as proof that heavier cannabis use is cardiovascular safe.

As cannabis legalization accelerates across the United States, clinicians and patients urgently need clarity on whether long-term cannabis exposure raises the risk of hypertension, one of the most prevalent and modifiable cardiovascular risk factors worldwide. Prior evidence has been limited by cross-sectional designs, single-time-point exposure measurement, and inadequate adjustment for confounders that change over time. A well-powered, decades-long prospective study using modern causal inference methods represents a meaningful step toward answering this question with the rigor it demands.

Hypertension remains the leading modifiable risk factor for cardiovascular disease globally, and its relationship to cannabis use has been a growing clinical concern amid expanding legalization. Prior studies examining this relationship have relied almost exclusively on cross-sectional data or retrospective recall of cannabis exposure, making them vulnerable to confounding by time-varying factors such as evolving smoking habits, alcohol intake, and weight changes. The present study draws on the CARDIA cohort, a multicenter prospective study that enrolled a balanced sample of Black and White young adults aged 18 to 30 from four US cities beginning in 1985. Researchers quantified cumulative cannabis exposure as “cannabis-years,” a novel metric analogous to pack-years in tobacco research, constructed from self-reported use frequency across 10 examination waves spanning 35 years. The study employed marginal structural Cox proportional hazards models with inverse probability weighting to account for the inherently dynamic relationship between cannabis exposure, time-varying confounders, and hypertension onset.

Among 4,328 eligible participants followed over 88,292 person-years, 2,478 incident cases of hypertension were documented at a rate of 28.1 per 1,000 person-years. The fully adjusted hazard ratio for cumulative cannabis-years was 0.99 (95% CI, 0.97 to 1.00; P = 0.18), indicating no statistically significant association. This null finding was consistent across multiple sensitivity analyses, including restricted cubic spline modeling, an alternative exposure metric of recent cannabis use days, and subgroup stratifications by sex, race, alcohol use, and tobacco smoking status. However, median cannabis-years in the cohort remained remarkably low throughout follow-up (0.0 at baseline, 0.2 at year 35), meaning the study primarily characterizes light-to-moderate use. The researchers appropriately note that cannabis potency, route of administration, and cannabinoid composition were not captured, and that results cannot be extrapolated to heavy, daily, or concentrate-based use patterns now common in legalized markets. The authors call for future research incorporating detailed product characterization and broader racial and ethnic diversity.

This study is a genuine methodological step forward. Using cannabis-years as a cumulative metric and applying marginal structural models to handle time-varying confounders gives us far more reliable estimates than the usual cross-sectional snapshot. The null finding over 35 years is reassuring in its consistency across subgroups. But the elephant in the room is exposure intensity: with median cannabis-years near zero even at the end of follow-up, this study really tells us about the cardiovascular profile of occasional or light users, not the daily concentrate user I increasingly see in my practice. That is a critically important distinction that should temper any celebratory headlines.

In my clinic, I use findings like these to provide honest reassurance to patients with light or moderate cannabis use histories who worry about their blood pressure. But I am careful not to extend that reassurance to patients using high-potency products daily or using concentrates, because this study simply does not speak to that population. I continue to monitor blood pressure regularly in all cannabis patients, discuss modifiable cardiovascular risk factors at every visit, and encourage patients to be forthcoming about their actual consumption patterns so we can make individualized assessments rather than relying on population averages.

This study occupies a meaningful position in the evolving research arc on cannabis and cardiovascular health. It directly addresses a limitation of prior work by quantifying cumulative, time-updated exposure rather than relying on ever-use or current-use categories. The CARDIA cohort is one of the few datasets capable of supporting this kind of analysis, given its 35-year duration and repeated assessments. However, the study sits at the observational tier of the evidence hierarchy, and even with marginal structural models, residual and unmeasured confounding cannot be ruled out. The cohort’s restriction to Black and White participants also limits the applicability of findings to an increasingly diverse patient population.

From a pharmacological standpoint, clinicians should bear in mind that acute cannabis use does transiently affect heart rate and blood pressure through cannabinoid receptor modulation, even if cumulative use may not translate into sustained hypertension in light users. Interactions between cannabis and common antihypertensive medications have not been well characterized in large

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care